Carborane compounds or their salts or solvates

Carborane compounds enhance CD28 binding to Grb2 SH2, addressing the high cost of existing biological agents by providing a small molecule alternative for treating autoimmune diseases and enhancing anti-tumor immune responses.

JP7768562B2Active Publication Date: 2025-11-12KYOTO PREFECTURAL PUBLIC UNIV CORP
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2022559147
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-10-30
Filing Date
2021-10-26
Publication Date
2025-11-12
Estimated Expiration
2041-10-26

AI Technical Summary

Technical Problem

Existing biological agents for treating autoimmune diseases and enhancing anti-tumor immune responses, such as Abatacept and anti-PD-1 antibodies, are expensive and pose a financial burden on patients and healthcare providers, necessitating the development of a small molecule drug that can act on the T cell receptor CD28 to suppress autoimmune diseases and enhance anti-tumor immune responses.

Method used

The development of carborane compounds that enhance the CD28 binding ability of Grb2 SH2 through high-resolution structural determination and docking simulations, leading to the discovery of candidate compounds that improve T cell signaling.

Benefits of technology

The carborane compounds enhance CD28-binding ability, potentially replacing costly biological agents and serving as lead compounds for drugs that suppress autoimmune diseases and enhance antitumor immune responses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007768562000016
    Figure 0007768562000016
  • Figure 0007768562000017
    Figure 0007768562000017
  • Figure 0007768562000018
    Figure 0007768562000018
Patent Text Reader

Abstract

The present invention provides a small molecule drug that is an agonist to T cell receptor CD28. Also, the present invention develops a lead compound in drug development, said lead compound being capable of suppressing autoimmune diseases and enhancing antitumor immune responses. A carborane compound represented by formula (1), a salt thereof or a solvate of the same (in the formula: R1 represents an amide bond-containing group; R2 and R3 are the same or different and represent a group containing a nitrogen-containing heterocycle; ● represents a carbon atom; and ○ represents a boron atom).
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Carborane compounds and methods of using them

    JP2018533621A

  • Immunopotentiating compositions

    WO2004004771A1

  • Pharmaceutical composition containing conjugate of boron-containing compound and protein

    WO2017026276A1